Gjærde, Lars Klingen http://orcid.org/0000-0002-5496-9955
Eeltink, Corien
Stringer, Jacqui
Mooyaart, Jarl
Bosman, Paul http://orcid.org/0000-0002-1473-9442
Kenyon, Michelle
Liptrott, Sarah http://orcid.org/0000-0001-9499-6002
Greenfield, Diana M. http://orcid.org/0000-0002-3733-2717
Linke, Andrea
Turlure, Pascal
Botti, Stefano http://orcid.org/0000-0002-0678-0242
Dzaferagic, Dzenana
Sica, Simona
Welsh, Lorna
Kisch, Annika http://orcid.org/0000-0002-1536-3926
Perić, Zinaida http://orcid.org/0000-0001-9458-8025
Schoemans, Hélène http://orcid.org/0000-0002-7568-8239
Murray, John
Funding for this research was provided by:
The Nurses Group of the European Society for Blood and Marrow Transplantation
Article History
Received: 13 June 2022
Revised: 28 October 2022
Accepted: 31 October 2022
First Online: 14 November 2022
Competing interests
: AL reports having received personal fees from Novartis and Bristol-Myers Squibb. HS reports having received personal fees from Incyte, Janssen, Novartis, Jazz Pharmaceuticals, Takeda, and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BH, paid to her institution. She has also received non-financial support from Incyte, Novartis, Gilead, the EBMT (European Society for Blood and Marrow Transplantation), and the CIBMTR (Center for International Bone Marrow Transplantation Research). JMu reports honorarium from Therakos, Jazz Pharmaceuticals, Janssen and Gilead/Kite. None of these potential conflicts of interest are relevant to this project. The rest of the authors declare no competing interests.